Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort

Clinical Endocrinology

Volumn 86, Issue 5, 2017, Pages 698-707

  Ajluni, Nevin ^a   Meral, Rasimcan ^a   Neidert, Adam H ^a   Brady, Graham F ^b   Buras, Eric ^a   McKenna, Barbara ^b   DiPaola, Frank ^c   Chenevert, Thomas L ^b   Horowitz, Jeffrey F ^c   Buggs Saxton, Colleen ^d   Rupani, Amit R ^c   Thomas, Peedikayil E ^c   Tayeh, Marwan K ^c   Innis, Jeffrey W ^c   Omary, M Bishr ^b   Conjeevaram, Hari ^b   Oral, Elif A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; HEMOGLOBIN; HEMOGLOBIN A1C; LEPTIN; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY COMPOSITION; BODY FAT; BODY MASS; BODY WEIGHT; CHILD; CHRONIC PAIN; CLINICAL ARTICLE; COHORT ANALYSIS; COMORBIDITY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; FAT CONTENT; FEMALE; FIBROSIS; GENE; GENE MUTATION; GENETIC VARIABILITY; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOFLUORESCENCE; LEG; LIPODYSTROPHY; LIVER BIOPSY; MALE; METABOLIC PARAMETERS; MIDDLE AGED; MOOD DISORDER; NAFLD ACTIVITY SCORE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTIAL LIPODYSTROPHY; POLD1 GENE; PRIORITY JOURNAL; SCHOOL CHILD; SKINFOLD THICKNESS; THROMBOCYTE COUNT; WAIST HIP RATIO; YOUNG ADULT; ADOLESCENT; GENETICS; LIPODYSTROPHY, FAMILIAL PARTIAL; METABOLISM; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; BODY COMPOSITION; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIPODYSTROPHY; LIPODYSTROPHY, FAMILIAL PARTIAL; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 85016320656     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.13311     Document Type: Article

References (38)

1. Chan, J.L. & Oral, E.A. (2010) Clinical classification and treatment of congenital and acquired lipodystrophy. Endocrine Practice, 16, 310–323.
2. Garg, A. (2011) Clinical review#: lipodystrophies: genetic and acquired body fat disorders. Journal of Clinical Endocrinology and Metabolism, 96, 3313–3325.
3. Handelsman, Y., Oral, E.A., Bloomgarden, Z.T. et al. (2013) The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocrine practice, 19, 107–116.
4. Vigouroux, C., Caron-Debarle, M., Le Dour, C. et al. (2011) Molecular mechanisms of human lipodystrophies: from adipocyte lipid droplet to oxidative stress and lipotoxicity. International Journal of Biochemistry & Cell Biology, 43, 862–876.
5. Farhan, S.M., Robinson, J.F., McIntyre, A.D. et al. (2014) A novel LIPE nonsense mutation found using exome sequencing in siblings with late-onset familial partial lipodystrophy. Canadian Journal of Cardiology, 30, 1649–1654.
6. Garg, A., Sankella, S., Xing, C. et al. (2016) Whole-exome sequencing identifies ADRA2A mutation in atypical familial partial lipodystrophy. JCI Insight, 1, e86870.
7. Haarbo, J., Gotfredsen, A., Hassager, C. et al. (1991) Validation of body composition by dual energy X-ray absorptiometry (DEXA). Clinical Physiology, 11, 331–341.
8. Kleiner, D.E., Brunt, E.M., Van Natta, M. et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 41, 1313–1321.
9. Speckman, R.A., Garg, A., Du, F. et al. (2000) Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C. American Journal of Human Genetics, 66, 1192–1198.
10. Subramanyam, L., Simha, V. & Garg, A. (2010) Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety & cardiomyopathy due to amino-terminal heterozygous missense lamin A/C mutations. Clinical Genetics, 78, 66–73.
11. Kalil, K.A. & Fargalley, H.S. (2012) Hypoparathyroidism in an Egyptian child with Hutchinson-Gilford progeria syndrome: a case report. Journal of Medical Case Reports, 6, 17.
12. Rauner, M., Sipos, W., Goettsch, C. et al. (2009) Inhibition of lamin A/C attenuates osteoblast differentiation and enhances RANKL-dependent osteoclastogenesis. Journal of Bone and Mineral Research, 24, 78–86.
13. Mory, P.B., Crispim, F., Freire, M.B. et al. (2012) Phenotypic diversity in patients with lipodystrophy associated with LMNA mutations. European Journal of Endocrinology, 167, 423–431.
14. Thong, K.M., Xu, Y., Cook, J. et al. (2013) Cosegregation of focal segmental glomerulosclerosis in a family with familial partial lipodystrophy due to a mutation in LMNA. Nephron. Clinical practice 124, 31–37.
15. Kelly, T.L., Wilson, K.E. & Heymsfield, S.B. (2009) Dual energy X-Ray absorptiometry body composition reference values from NHANES. PLoS One, 4, e7038.
16. Fan, B., Shepherd, J.A., Levine, M.A. et al. (2014) National Health and Nutrition Examination Survey whole-body dual-energy X-ray absorptiometry reference data for GE Lunar systems. Journal of clinical densitometry, 17, 344–377.
17. McDowell, M.A., Fryar, C.D. & Ogden, C.L. (2009) Anthropometric reference data for children and adults: united States, 1988-1994. Vital Health Statistics 11, 249, 1–68.
18. Diker-Cohen, T., Cochran, E., Gorden, P. et al. (2015) Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. Journal of Clinical Endocrinology and Metabolism, 100, 1802–1810.
19. Ajluni, N., Dar, M., Xu, J. et al. (2016) Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program. Journal of Diabetes & Metabolism, 7, 659.
20. Szczepaniak, L.S., Nurenberg, P., Leonard, D. et al. (2005) Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. American Journal of Physiology. Endocrinology and Metabolism, 288, E462–E468.
21. Bashaw, E.D. (2016) A clinical pharmacology-regulatory perspective on the approval of drugs for rare diseases. Clinical Pharmacology and Therapeutics, 100, 327–329.
22. Jeru, I., Vatier, C., Araujo-Vilar, D. et al. (2017) Gene, clinical utility card for: familial partial lipodystrophy. European Journal of Human Genetics, 25, e1–e3.
23. Jeru, I., Vatier, C., Araujo-Vilar, D. et al. (2016) Clinical utility gene card for: congenital generalized lipodystrophy. European Journal of Human Genetics, 24, e1–e4.
24. Lotta, L.A., Gulati, P., Day, F.R. et al. (2017) Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nature Genetics, 49, 17–26.
25. Weedon, M.N., Ellard, S., Prindle, M.J. et al. (2013) An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. Nature Genetics, 45, 947–950.
26. Misra, A., Peethambaram, A. & Garg, A. (2004) Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore), 83, 18–34.
27. Brown, R.J., Araujo-Vilar, D., Cheung, P.T. et al. (2016) The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. Journal of Clinical Endocrinology and Metabolism, 101, 4500–4511.
28. Guillin-Amarelle, C., Sanchez-Iglesias, S., Castro-Pais, A. et al. (2016) Type 1 familial partial lipodystrophy: understanding the Kobberling syndrome. Endocrine, 54, 411–421.
29. Beraldo, R.A., Vassimon, H.S., Aragon, D.C. et al. (2015) Proposed ratios and cutoffs for the assessment of lipodystrophy in HIV-seropositive individuals. European Journal of Clinical Nutrition, 69, 274–278.
30. Van Pelt, R.E., Evans, E.M., Schechtman, K.B. et al. (2002) Contributions of total and regional fat mass to risk for cardiovascular disease in older women. American Journal of Physiology. Endocrinology and Metabolism, 282, E1023–E1028.
31. Van Pelt, R.E., Jankowski, C.M., Gozansky, W.S. et al. (2005) Lower-body adiposity and metabolic protection in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 90, 4573–4578.
32. Hernandez, T.L., Bessesen, D.H., Cox- York, K.A. et al. (2015) Femoral lipectomy increases postprandial lipemia in women. American Journal of Physiology. Endocrinology and Metabolism, 309, E63–E71.
33. Portillo-Sanchez, P., Bril, F., Maximos, M. et al. (2015) High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. Journal of Clinical Endocrinology and Metabolism, 100, 2231–2238.
34. Simha, V., Subramanyam, L., Szczepaniak, L. et al. (2012) Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. Journal of Clinical Endocrinology and Metabolism, 97, 785–792.
35. Iglay, K., Hannachi, H., Joseph Howie, P. et al. (2016) Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Current Medical Research and Opinion, 32, 1243–1252.
36. Anderson, R.J., Freedland, K.E., Clouse, R.E. et al. (2001) The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care, 24, 1069–1078.
37. Guenantin, A.C., Briand, N., Bidault, G. et al. (2014) Nuclear envelope-related lipodystrophies. Seminars in Cell & Developmental Biology, 29, 148–157.
38. Weinreb, N.J., Cappellini, M.D., Cox, T.M. et al. (2010) A validated disease severity scoring system for adults with type 1 Gaucher disease. Genetics in Medicine, 12, 44–51.